These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 36576430)

  • 21. Is there still a role for sorafenib in metastatic renal cell carcinoma? A systematic review and meta-analysis of the effectiveness of sorafenib over other targeted agents.
    Iacovelli R; Verri E; Cossu Rocca M; Aurilio G; Cullurà D; Santoni M; de Cobelli O; Nolé F
    Crit Rev Oncol Hematol; 2016 Mar; 99():324-31. PubMed ID: 26818051
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Small molecule targeted therapies for the second-line treatment for metastatic renal cell carcinoma: a systematic review and indirect comparison of safety and efficacy.
    Dranitsaris G; Schmitz S; Broom RJ
    J Cancer Res Clin Oncol; 2013 Nov; 139(11):1917-26. PubMed ID: 24037486
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The role of tivozanib in advanced renal cell carcinoma therapy.
    Escudier B; Porta C; Eisen T; Belsey J; Gibson D; Morgan J; Motzer R
    Expert Rev Anticancer Ther; 2018 Nov; 18(11):1113-1124. PubMed ID: 30084668
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Final Data Analysis Supports Tivozanib as Superior Treatment for Patients With RCC.
    Wright KM
    Oncology (Williston Park); 2020 Jul; 34(7):257. PubMed ID: 32674211
    [TBL] [Abstract][Full Text] [Related]  

  • 25. First-line axitinib versus sorafenib in Asian patients with metastatic renal cell carcinoma: exploratory subgroup analyses of Phase III data.
    Sheng X; Bi F; Ren X; Cheng Y; Wang J; Rosbrook B; Jiang M; Guo J
    Future Oncol; 2019 Jan; 15(1):53-63. PubMed ID: 30058839
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cost analysis for different sequential treatment regimens for metastatic renal cell carcinoma in China.
    Shi G; Park SH; Ren H; Xue M; Lu X; Dong P; Gao X
    J Med Econ; 2018 Dec; 21(12):1150-1158. PubMed ID: 30134758
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Safety and Efficacy of Tivozanib in First-Line mRCC: A Multicenter Compassionate-Use Study (Meet-Uro 16).
    Basso U; Procopio G; Fornarini G; Massari F; Bearz A; Fratino L; Milella M; Bassanelli M; Ermacora P; Bimbatti D; Verzoni E; Rizzo M; Porta C
    Oncology; 2021; 99(12):747-755. PubMed ID: 34583356
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Current Status of Tivozanib in the Treatment of Patients With Advanced Renal Cell Carcinoma.
    Sakellakis M; Zakopoulou R
    Cureus; 2023 Mar; 15(3):e35675. PubMed ID: 37012938
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Phase II study of axitinib in sorafenib-refractory metastatic renal cell carcinoma.
    Rini BI; Wilding G; Hudes G; Stadler WM; Kim S; Tarazi J; Rosbrook B; Trask PC; Wood L; Dutcher JP
    J Clin Oncol; 2009 Sep; 27(27):4462-8. PubMed ID: 19652060
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Early Tumour Shrinkage: A Tool for the Detection of Early Clinical Activity in Metastatic Renal Cell Carcinoma.
    Grünwald V; Lin X; Kalanovic D; Simantov R
    Eur Urol; 2016 Dec; 70(6):1006-1015. PubMed ID: 27238653
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Is Axitinib Still a Valid Option for mRCC in the Second-Line Setting? Prognostic Factor Analyses From the AXIS Trial.
    Bracarda S; Bamias A; Casper J; Negrier S; Sella A; Staehler M; Tarazi J; Felici A; Rosbrook B; Jardinaud-Lopez M; Escudier B
    Clin Genitourin Cancer; 2019 Jun; 17(3):e689-e703. PubMed ID: 31072748
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antitumor activity and safety of tivozanib (AV-951) in a phase II randomized discontinuation trial in patients with renal cell carcinoma.
    Nosov DA; Esteves B; Lipatov ON; Lyulko AA; Anischenko AA; Chacko RT; Doval DC; Strahs A; Slichenmyer WJ; Bhargava P
    J Clin Oncol; 2012 May; 30(14):1678-85. PubMed ID: 22493422
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A Systematic Review and Meta-analysis Comparing the Effectiveness and Adverse Effects of Different Systemic Treatments for Non-clear Cell Renal Cell Carcinoma.
    Fernández-Pello S; Hofmann F; Tahbaz R; Marconi L; Lam TB; Albiges L; Bensalah K; Canfield SE; Dabestani S; Giles RH; Hora M; Kuczyk MA; Merseburger AS; Powles T; Staehler M; Volpe A; Ljungberg B; Bex A
    Eur Urol; 2017 Mar; 71(3):426-436. PubMed ID: 27939075
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Tivozanib: status of development.
    Jamil MO; Hathaway A; Mehta A
    Curr Oncol Rep; 2015 Jun; 17(6):24. PubMed ID: 25895472
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Drug-Induced Hypertension Caused by Multikinase Inhibitors (Sorafenib, Sunitinib, Lenvatinib and Axitinib) in Renal Cell Carcinoma Treatment.
    Bæk Møller N; Budolfsen C; Grimm D; Krüger M; Infanger M; Wehland M; E Magnusson N
    Int J Mol Sci; 2019 Sep; 20(19):. PubMed ID: 31547602
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy and Safety of Selective Vascular Endothelial Growth Factor Receptor Inhibitors Compared with Sorafenib for Metastatic Renal Cell Carcinoma: a Meta-analysis of Randomised Controlled Trials.
    Kang SK; Volodarskiy A; Ohmann EL; Balar AV; Bangalore S
    Clin Oncol (R Coll Radiol); 2016 May; 28(5):334-41. PubMed ID: 26723100
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy, Safety, and Tolerability of Tivozanib in Heavily Pretreated Patients With Advanced Clear Cell Renal Cell Carcinoma.
    Johns AC; Campbell MT; Gao M; Hahn AW; Lim Z; Wang E; Gao J; Shah AY; Msaouel P; Tannir NM
    Oncologist; 2024 Jul; 29(7):589-595. PubMed ID: 38478923
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A Prospectivly Randomized Phase-II Trial of Axitinib versus Everolimus as Second-Line Therapy in Metastatic Renal Cell Carcinoma (BERAT Study).
    Grünwald V; Hilser T; Meiler J; Goebell PJ; Ivanyi P; Strauss A; Hartmann A; Bedke J; Bergmann L
    Oncol Res Treat; 2022; 45(5):272-280. PubMed ID: 35045416
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Hypertension among patients with renal cell carcinoma receiving axitinib or sorafenib: analysis from the randomized phase III AXIS trial.
    Rini BI; Quinn DI; Baum M; Wood LS; Tarazi J; Rosbrook B; Arruda LS; Cisar L; Roberts WG; Kim S; Motzer RJ
    Target Oncol; 2015 Mar; 10(1):45-53. PubMed ID: 24595903
    [TBL] [Abstract][Full Text] [Related]  

  • 40. An Open Label Phase Ib Dose Escalation Study of TRC105 (Anti-Endoglin Antibody) with Axitinib in Patients with Metastatic Renal Cell Carcinoma.
    Choueiri TK; Michaelson MD; Posadas EM; Sonpavde GP; McDermott DF; Nixon AB; Liu Y; Yuan Z; Seon BK; Walsh M; Jivani MA; Adams BJ; Theuer CP
    Oncologist; 2019 Feb; 24(2):202-210. PubMed ID: 30190302
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.